Aligos Therapeutics (ALGS) Long-Term Investments (2019 - 2021)
Aligos Therapeutics' (ALGS) quarterly Long-Term Investments came in at $15.1 million in Q4 2021, up 2971.14% on a QoQ basis from $492000.0 in Q3 2021.
Aligos Therapeutics (ALGS) Long-Term Investments (2019 - 2021) Analysis & Trends
Aligos Therapeutics (ALGS) has 2 years of Long-Term Investments data on file, last reported at $15.1 million in Q4 2021.
- Quarterly Long-Term Investments changed N/A year-over-year to $15.1 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $15.1 million (changed N/A YoY) and the FY2021 annual result came in at $15.1 million, changed N/A from the prior year.
- Long-Term Investments grew to $15.1 million in Q4 2021, from $492000.0 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $15.1 million in Q4 2021 to a low of $492000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 15.11 Mn |
| Sep 30, 2021 | 492,000.00 |
| Dec 31, 2019 | 10.02 Mn |